Nasdaq1mon
Rezolute Provides Update On Phase 3 SunRIZE Study Of Ersodetug For Congenital Hyperinsulinism
(RTTNews) - Rezolute, Inc. (RZLT), a late-stage biopharmaceutical company focused on rare diseases, provided an update on its Phase 3 sunRIZE study of ersodetug for the treatment of hypoglycemia ...
Nasdaq1mon
Rezolute, Inc. Reports Positive DMC Review of sunRIZE Study for Ersodetug in Infants with Hyperinsulinism
Rezolute, Inc. announced that the Data Monitoring Committee (DMC) has reviewed the open-label arm of its Phase 3 sunRIZE study for the treatment of congenital hyperinsulinism with ersodetug in ...
Business Insider1mon
Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
“We are encouraged by these preliminary outcomes from the open label arm of the sunRIZE study, particularly as it is a strong indication of the safety profile of ersodetug and provides ...